Please login to the form below
NSCLC
This page shows the latest NSCLC news and features for those working in and with pharma, biotech and healthcare.
NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
It is estimated that over 34, 000 people in England are diagnosed with NSCLC each year, with roughly 20% of these patients receiving a diagnosis at stage 3. ... There are treatment options available for those diagnosed with stage 3 NSCLC, however if a
Latest news
-
Enhertu to provide patients with vital targeted therapy option
While HER2 gene mutations can occur in a range of patients, they are more commonly found in those with NSCLC who are younger, female and have never smoked. ... For patients with metastatic NSCLC, prognosis is particularly poor, as only approximately 8%
-
ICR scientists create AI test to predict cancer drug combinations
The scientists tested the new technique on individual cancer cells in the lab, and on tumour cells isolated from lung fluid in patients diagnosed with non-small cell lung cancer (NSCLC). ... Additionally, the test successfully identified combinations
-
FDA approves BMS’ Opdivo with chemotherapy for certain lung cancer patients
The approval of the intravenous treatment is only for some adult patients with resectable non-small cell lung cancer (NSCLC). ... The standard of care for resectable NSCLC is surgery, but the cancer recurs in 30% to 55% of patients who have surgery.
-
NICE recommends Amgen’s Lumykras for non-small-cell lung cancer
The CMA for Lumykras is based on clinical evidence from the phase 2 CodeBreaK 100 trial which evaluated the drug in 126 patients with KRAS G12C- mutated advanced NSCLC. ... mutation. More than half of NSCLC patients have advanced or metastatic disease at
-
New drug available on NHS will benefit lung cancer patients
Over 850 patients in England diagnosed with NSCLC will be able to access the treatment in year one, with numbers tipped to rise to more than 1, 000 patients in year ... Following approval from the Medicines and Healthcare products Regulatory Agency (MHRA)
More from news
Approximately 146 fully matching, plus 412 partially matching documents found.
Latest Intelligence
-
Unlocking the potential of precision medicine in oncology
Targeted therapies. Furthermore, by following a similar trajectory in the treatment of non-small cell lung cancer (NSCLC), where we are studying specific alterations in the epidermal growth factor receptor (EGFR), ... Our teams of clinical researchers
-
20 for 2020 – Five pharma companies to watch
Tagrisso’s growth as it moves earlier in the treatment pathway for EGFR-positive non-small lung cancer (NSCLC) and launches in new markets like China, plus possible label extensions for ... checkpoint inhibitor Imfinzi such as the POSEIDON trial in
-
Encouraging signs in biomarker R&D
impact of Opdivo plus Yervoy on OS in first-line NSCLC patients’.
-
Immuno-oncology in 2019: the rapid evolution continues
2019. The only drug that has any realistic chance of challenging Keytruda in NSCLC is Roche’s Tecentriq. ... The Tecentriq chemo trial, IMpower132, is the most important head-to-head with Keytruda (in non-squamous NSCLC).
-
Is China ready for a pharmaceutical gold rush?
Bristol-Myers Squibb’s (BMS)’s Opdivo (nivolumab) was approved for the treatment of non-small cell lung cancer (NSCLC) in June.
More from intelligence
Approximately 1 fully matching, plus 15 partially matching documents found.
Latest appointments
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
newly-diagnosed non-small cell lung cancer (NSCLC) patients.
-
Astellas bolsters oncology clinical development leadership
the clinical development programme for Astellas' NSCLC candidate, ASP8273.
-
Axelar appoints Carl Harald Janson as CEO
The biotech is currently running a randomised phase II clinical trial with AXL1717 in non-small cell lung cancer (NSCLC) patients, while a first-in-man phase I/II clinical trial
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Delphi Technique Virtual Co-creation: A Customer Story
The client’s main objectives were to:. Determine the current barriers to biomarker testing and biomarker-based treatment for non-small cell lung cancer (NSCLC), including differences in regional access and ... Leverage the Delphi technique to co-create
-
How scenario testing helped assess demand for a brand launch in the fragmented NSCLC market
Our client was developing a new drug aimed at first line NSCLC patients.
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
-
Therapy Watch expands its oncology portfolio
Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal
-
How pembrolizumab will change the management of advanced lung cancer
The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by VJOncology Editorial Board Member Dr Martin Reck of LungenClinic Grosshansdorf. ... high expressing NSCLC.
More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
-
Head of Health Psychology, London
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
-
Senior Health Psychologist, London
-
Highly competitive salary
- Scientists discover new approach to treat brain tumours
- Recognising HIV Vaccine Awareness Day
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- UICC launches global ATOM Coalition to increase access to essential cancer medicines
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- Live Webinar: The Future of MedTech: Streamlined Clinical Data Collection & Management
- Medscape: Connect to the conversation
- A Medscape 4-part video interview series
- Why big pharma needs to be braver
- MadMicrobe Studios Inc Announces New European Venture
- EMA accepts Valneva’s marketing authorisation application for COVID-19 vaccine
PMHub
Graphite Digital
We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...
Latest intelligence
- Why big pharma needs to be braver
- The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
- Food Allergy – Is avoidance the only option?
- Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
